Compass Financial Group INC SD Takes $673,000 Position in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on May 8th, 2023

Compass Financial Group INC SD acquired a new position in Johnson & Johnson (NYSE:JNJ – Get Rating) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 3,809 shares of the company’s stock, valued at approximately $673,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Lincoln Capital Corp increased its holdings in shares of Johnson & Johnson by 15.9% during the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after acquiring an additional 183 shares in the last quarter. Ieq Capital LLC boosted its position in Johnson & Johnson by 5.1% in the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after purchasing an additional 6,154 shares during the last quarter. RFG Advisory LLC raised its stake in shares of Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after purchasing an additional 594 shares during the period. Willis Investment Counsel raised its stake in shares of Johnson & Johnson by 0.4% during the 4th quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock valued at $58,097,000 after purchasing an additional 1,358 shares during the period. Finally, Wambolt & Associates LLC increased its stake in Johnson & Johnson by 2.5% in the 4th quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock worth $2,566,000 after acquiring an additional 355 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $162.68 on Monday. The company has a market cap of $422.76 billion, a P/E ratio of 34.03, a price-to-earnings-growth ratio of 2.77 and a beta of 0.53. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.77. The stock’s fifty day moving average price is $158.33 and its 200-day moving average price is $166.98.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period last year, the business posted $2.67 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be given a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 2.93%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s payout ratio is presently 94.56%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. UBS Group assumed coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price on the stock. Guggenheim started coverage on Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price for the company. SVB Leerink dropped their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Credit Suisse Group increased their target price on Johnson & Johnson from $168.00 to $170.00 in a report on Friday. Finally, Raymond James dropped their target price on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday, April 19th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.